3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
60
Burkitt Lymphoma
10
Recurrence
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Large B-Cell, Diffuse
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms, Plasma Cell
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell
3
Lung Neoplasms
3
Leukemia, Biphenotypic, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Waldenstrom Macroglobulinemia
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Immunoglobulin Light-chain Amyloidosis
2
Down Syndrome
2
Uterine Cervical Neoplasms
1
Smoldering Multiple Myeloma
1
Rectal Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Plasmacytoma
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Interventions
pomalidomide
1
daratumumab
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Plasmacytoma
×
Dexamethasone
×
30 days
×
Clear all
NCT01946477
2026-05-22
POM MM 014
Celgene
Phase 2
Completed
186 enrolled
17 charts